Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
about
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesStatin therapy and autoimmune disease: from protein prenylation to immunomodulationRHOA is a modulator of the cholesterol-lowering effects of statinStatins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus BiofilmEffect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients.Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress.Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with DiabetesStatins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heartAtorvastatin protects against cerebral ischemia/reperfusion injury through anti-inflammatory and antioxidant effectsInhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts.Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort studyStatin improves flow-mediated vasodilation in chronic kidney diseases.Targeting tumor cell metabolism with statins.The controversy of a wider statin utilization: why?Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis.Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications.Statin use and risk of Parkinson's disease: a meta-analysis of observational studies.Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells.Cytotoxic effects of statins and thiazolidinediones on meningioma cells.Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signalingIncreased expression of CD14 in macrophages after inhibition of the cholesterol biosynthetic pathway by lovastatin.Atorvastatin: beyond lipid-lowering effects in the diabetic population.Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure.Pravastatin improves the impaired nitric oxide-mediated neurogenic and endothelium-dependent relaxation of corpus cavernosum in aged rats.Graft-versus-host disease: suppression by statins.Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.Statin use and vitreoretinal surgery: Findings from a Finnish population-based cohort study.Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats.Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial)Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patientsPravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition
P2860
Q26746907-BFF32A8B-3B71-42AD-B6CE-87C3316D46D8Q28236647-E52DEFF2-9162-4CAE-91C4-D710100968FFQ28485187-B7EA63EE-40E0-469D-8445-61E49BDD04CDQ28547567-7F21FAC9-387E-4FD9-8A98-7E32116C457BQ33655267-97486624-C0CA-4B2F-B04B-9448A0BC046AQ33835644-3E3655E0-D368-4D83-8F1F-5A54DC0D076AQ33889894-CF80C38D-CDD4-4609-87EA-674E850C62C1Q34024078-7B2EA2AB-306F-4AA2-AD97-C10BFD652521Q34095633-151ED568-A40C-4EC0-92D2-B874FE98A576Q34538139-E8D2C8C3-F339-4E32-843C-E18C2904DC4DQ37074239-5A7D3B4D-D092-410D-B62A-F86272C70F92Q37202140-C5E331F4-4FCD-4CCF-8B1F-AE7BE9A3D55CQ37293275-1FBA4E82-E238-4BA5-861C-01AF8FA48EABQ37417376-165B9D59-81E0-44E6-BC41-005B073E85C9Q37981833-F010F60D-6534-4A8D-80C6-B7F880EEC329Q38089090-25130696-0777-4EC8-BB76-967B821C11EBQ38101731-A5A647D5-C5EB-45CE-A4F5-55934A4E9E17Q39043383-F5200216-2525-4548-8938-68A55A4DA64DQ39212423-1D882B23-AD10-4E41-9688-29E12B36F6F3Q39582097-B176CEF4-C52A-4B34-9BC9-3AAD1E2964C7Q39625491-F28AEFDB-2FA2-4044-9E3E-6F3FEF8A950CQ39661946-A62E748C-B455-41F3-A8A4-E6A4932D6EF0Q39948284-F1DDB62D-8379-4525-9FE3-FFA89C79A421Q40068676-05779709-7F69-46AC-84AB-3FF0269DDC54Q40292972-5467788F-4B70-4F8A-8841-DFDE50AB7BE6Q41165858-1BF576FF-05DE-4D28-943D-204FFFE5F54BQ42133595-26E99E78-7982-462F-93B3-0013147B2231Q43248481-3C835DBA-7923-4CFB-94CA-4AFA9D89C08FQ43690803-30ADC484-EDA0-439C-9EDC-B0004DB0C5E5Q43780095-D57C0C31-C322-4CA3-A8A4-2E74FF16E529Q47696088-0B97EC5B-697A-43AC-9EDB-A150C9113512Q48234715-D243C25B-A142-4865-890D-255948F4E8E5Q53211713-FBAEEB64-7615-4F72-A0F5-9E39C9E1417BQ57816063-4A0FB4D8-E695-4F92-A35F-B141525AC044Q58075251-5DDC4EA3-BAF8-409B-8629-2B08951683B8Q59045212-EA9D481F-D082-42BF-B20C-5CA1448A1FA2
P2860
Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Intermolecular differences of ...... logic and pleiotropic actions.
@ast
Intermolecular differences of ...... logic and pleiotropic actions.
@en
type
label
Intermolecular differences of ...... logic and pleiotropic actions.
@ast
Intermolecular differences of ...... logic and pleiotropic actions.
@en
prefLabel
Intermolecular differences of ...... logic and pleiotropic actions.
@ast
Intermolecular differences of ...... logic and pleiotropic actions.
@en
P2093
P1476
Intermolecular differences of ...... logic and pleiotropic actions.
@en
P2093
Mary F Walter
R Preston Mason
Robert F Jacob
P304
P356
10.1016/J.AMJCARD.2005.06.008
P407
P577
2005-09-01T00:00:00Z